Abstract
Delivery of plasmid DNA encoding an antigen of interest has been demonstrated to be an effective means of immunization, capable of eliciting antigen-specific T cells. Plasmid DNA vaccines offer advantages over other anti-tumor vaccine approaches in terms of simplicity, manufacturing, and possibly safety. The primary disadvantage is their poor transfection efficiency and subsequent lower immunogenicity relative to other genetic vaccine approaches. However, multiple preclinical models demonstrate anti-tumor efficacy, and many efforts are underway to improve the immunogenicity and anti-tumor effect of these vaccines. Clinical trials using DNA vaccines as treatments for prostate cancer have begun, and to date have demonstrated safety and immunological effect. This review will focus on DNA vaccines as a specific means of antigen delivery, advantages and disadvantages of this type of immunization, previous experience in preclinical models and human trials specifically conducted for the treatment of prostate cancer, and future directions for the application of DNA vaccines to prostate cancer immunotherapy.
Keywords: DNA vaccines, prostate cancer, tumor antigens, clinical trials
Current Cancer Therapy Reviews
Title:DNA Vaccines for Prostate Cancer
Volume: 8 Issue: 4
Author(s): Douglas G. McNeel, Jordan T. Becker, Laura E. Johnson and Brian M. Olson
Affiliation:
Keywords: DNA vaccines, prostate cancer, tumor antigens, clinical trials
Abstract: Delivery of plasmid DNA encoding an antigen of interest has been demonstrated to be an effective means of immunization, capable of eliciting antigen-specific T cells. Plasmid DNA vaccines offer advantages over other anti-tumor vaccine approaches in terms of simplicity, manufacturing, and possibly safety. The primary disadvantage is their poor transfection efficiency and subsequent lower immunogenicity relative to other genetic vaccine approaches. However, multiple preclinical models demonstrate anti-tumor efficacy, and many efforts are underway to improve the immunogenicity and anti-tumor effect of these vaccines. Clinical trials using DNA vaccines as treatments for prostate cancer have begun, and to date have demonstrated safety and immunological effect. This review will focus on DNA vaccines as a specific means of antigen delivery, advantages and disadvantages of this type of immunization, previous experience in preclinical models and human trials specifically conducted for the treatment of prostate cancer, and future directions for the application of DNA vaccines to prostate cancer immunotherapy.
Export Options
About this article
Cite this article as:
G. McNeel Douglas, T. Becker Jordan, E. Johnson Laura and M. Olson Brian, DNA Vaccines for Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040245
DOI https://dx.doi.org/10.2174/1573394711208040245 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Recent Development in the Synthesis of Eco-Friendly Polymeric Antioxidants
Current Organic Chemistry High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Leukopenia Associated with Risperidone Treatment
Current Drug Safety QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells
Current Pharmaceutical Biotechnology Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Editorial
Current Medical Imaging Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
Current Pharmaceutical Design Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry